Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|October 27, 2021
Daily Medication Pearl: Apremilast (Otezla)
Author(s)Saro Arakelians, PharmD
Apremilast is indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behçet disease.
Advertisement
Medication Pearl of the Day: Apremilast (Otezla)
Indication: Apremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of adult patients with active psoriatic arthritis; adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; and adult patients with oral ulcers associated with Behçet’s disease.
Insight:
- Dosing: To reduce the risk of gastrointestinal symptoms, titrate to recommended dose of 30 mg twice daily from 10 mg, once a day, to twice a day, then 20 mg, then 30 mg within 6 days.
- Dosage form: Tablets 10 mg, 20 mg, and 30 mg.
- Adverse events (AEs): The most common AEs (≥ 5%) are diarrhea, nausea, headache, and upper respiratory tract infection.
- Mechanism of action:Apremilast is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels.
- Manufacturer: Amgen
Sources:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5